Clinical trials: Staphylococcus Infections
Staphylococcus (S.) Aureus Infection
Staphylococcus Aureus Caught in Action at the Site of Infection
This study is to obtain a comprehensive view of S. aureus adaptations in the infected human host and (i) to improve the understanding of the interface between antibiotic therapy, resistance development and virulence factor…
- Trial name
- PROSA (NCT04781569)
- Testing
- data collection, blood draw, nose swabs
- Where
- Switzerland
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- University Hospital, Basel, Switzerland
Staphylococcus Aureus
A Study to Investigate the Transmission and Burden of PVL-MRSA in Households in Sri Lanka
This study will determine the frequency of Staphylococcus aureus carriage in household contacts of individuals with clinical infection due to this pathogen.
- Trial name
- NCT04884958
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- University of Sheffield
Staphylococcus Aureus Skin Infection
Human Immunity Against Staphylococcus Aureus Skin Infection
Background: Staphylococcus aureus, or staph, is commonly found on the skin and in the respiratory system. Sometimes people who get sick with staph infection do not get better with standard treatment.
- Trial name
- NCT02262819
- Testing
- S. aureus
- Where
- United States
- Volunteers
- 49 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Staphylococcus Aureus Infection
A Clinical Trial to Evaluate a Recombinant Staphylococcus Aureus Vaccine (Escherichia Coli) in Healthy Adults
This is a single center, open-label phase1b clinical trial. The study will evaluate the safety and immunogenicity of an experimental recombinant staphylococcus aureus vaccine with different immunization schedules in healthy…
- Trial name
- NCT03966040
- Testing
- Inoculate Staphylococcus aureus vaccine(Escherichia Coli) at day 0-3-7, Inoculate Staphylococcus aureus vaccine(Escherichia Coli) at day 0/0-3-7, Inoculate Staphylococcus aureus vaccine(Escherichia Coli) at day 0/0-7
- Where
- China
- Volunteers
- 144 people, healthy volunteers welcome
- Sponsor
- Jiangsu Province Centers for Disease Control and Prevention
Staphylococcus Aureus
S. Aureus Translocation From Skin and Nose to Periprosthetic Tissues
Surgical site infections (SSI) are a significant clinical issue that requires the use of a great amount of resources. In particular, periprosthetic joint infections (PJIs) have potentially catastrophic effects on patients'…
- Trial name
- NCT04666532
- Where
- United States
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Rothman Institute Orthopaedics
Staphylococcus Aureus, Next Generation Sequencing
MSSA and MRSA Screening in Patients Undergoing Elective TJA: the Benefits of Next-generation Sequencing
The aims of this study were to evaluate the diagnostic performance of molecular and culture techniques in S. aureus screening using paired nasal and groin swabs, to determine, if any, discrepancy between the diagnostic techniques…
- Conditions
- Staphylococcus Aureus, Next Generation Sequencing, Total Joint Arthroplasty
- Trial name
- NCT04574752
- Testing
- next generation sequencing
- Where
- United States
- Volunteers
- 163 people, healthy volunteers welcome
- Sponsor
- Rothman Institute Orthopaedics
Staphylococcus Aureus Bloodstream Infections (BSI; Bacteremia)
A Placebo-Controlled, Dose-Escalating Study to Examine the Safety and Tolerability of Single Intravenous Doses of CF-301 in Healthy Subjects
A Phase 1, Placebo-Controlled, Dose-Escalating Study to Examine the Safety and Tolerability of Single Intravenous Doses of CF-301 in Healthy Subjects.
- Trial name
- NCT02439359
- Testing
- CF-301
- Where
- 2 sites in United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- ContraFect
Staphylococcus Aureus
Evaluation of NDV-3A Vaccine in Preventing S. Aureus Colonization
The proposed study aims to further evaluate the safety and immunogenicity of a candidate S. aureus vaccine NDV-3A, as well as its efficacy against acquisition of S. aureus
- Trial name
- NCT03455309
- Testing
- NDV-3A
- Where
- United States
- Volunteers
- 382 people, healthy volunteers welcome
- Sponsor
- NovaDigm Therapeutics, Inc.
Wound Infection Due to Staphylococcus Aureus, MRSA Infection of Postoperative Wound
S. Aureus Screening and Decolonization
Staphylococcus aureus (SA) healthcare-associated infections (HAI) cause significant morbidity and mortality. SA causes 15% of all HAI and 30% of surgical site infections (SSIs).
- Trial name
- NCT02182115
- Testing
- antiseptic bundle, standard of care
- Where
- United States
- Volunteers
- 110 people, healthy volunteers welcome
- Sponsor
- University of Minnesota
Staphylococcus Aureus
Mother to Newborn Transmission of Staphylococcus Aureus and Dynamics of S.Aureus Carriage During the First Years Life
Staphylococcus aureus (SA) is a significant cause of community and hospital acquired infections. SA is carried by approximately 30% of healthy adults. Similar carriage rates have been reported in very young infants and newborns.
- Trial name
- NCT03064373
- Where
- Israel
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- Sheba Medical Center
Staphylococcus Aureus Infection
Study of the Nasal Decolonisation of Staphylococcus Aureus (SA) and the Safety and Tolerability of XF-73 Nasal Gel in Healthy Subjects
Study to determine the efficacy, safety and tolerability of two concentrations of XF-73 nasal gel in combination with body and face washing with chlorhexidine gluconate cloths in eradicating nasal carriage of Staphylococcus…
- Trial name
- NCT02282605
- Testing
- XF-73 nasal gel, Chlorhexidine gluconate 2% topical cloths
- Where
- United Kingdom
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Destiny Pharma Plc
Folliculitis Decalvans, Staphylococcus Aureus
Impact of Staphylococcus Aureus on Folliculitis Decalvans
The folliculitis decalvans (FD) is an orphan disease , common in consultation specialized on scalp. This disease is currently not curable, responsible for significant for patients.
- Trial name
- SAFE (NCT02157688)
- Testing
- no intervention : case control study
- Where
- France
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Nasal Carriage of Staphylococcus Aureus
Staphylococcus Aureus Nasal Carriage
The repeated exposition to S. aureus is considered as a determining factor of acquisition of the nasal colonization. The healthcare professionals are regularly in touch with this pathogenic bacterium.
- Trial name
- SANAC (NCT02796690)
- Testing
- nasal swabs will be collected
- Where
- France
- Volunteers
- 310 people, healthy volunteers welcome
- Sponsor
- Hospices Civils de Lyon
Community-acquired Methicillin-resistant Staphylococcus Aureus Infection
New Mexico Honey Wound Treatment Research Study
In a time of emerging bacteria that are resistant to antibiotics, honey offers an alternative that has potential to reduce the heavy reliance on pharmaceutical antibiotics.
- Trial name
- NCT01748318
- Testing
- New Mexico Honey, Bactrim DS
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- R. Stephen Rankin, M.D.
Abscess, Methicillin-Resistant Staphylococcus Aureus Infection
Trial of Septra for Uncomplicated Skin Abscesses in Patients at Risk for Community Acquired Methicillin-Resistant Staphylococcus Aureus Infection
Patients will be enrolled in a multi-center study (Wilford Hall Medical Center and Brooke Army Medical Center) to prospectively evaluate outcome after treatment for an uncomplicated skin abscess.
- Trial name
- NCT00822692
- Testing
- Trim/ Sulfa DS
- Where
- United States
- Volunteers
- 139 people, healthy volunteers welcome
- Sponsor
- 59th Medical Wing
Nasal Carriers of Staphylococcus Aureus
Clearance of Nasal Staphylococcus Aureus With Triple Antibiotic Ointment
Staphylococcus aureus, a bacteria that lives commonly in the anterior nostrils, is seen in about 30% of healthcare workers. Applying mupirocin ointment, a prescription, to the nostrils twice daily for 5 days is the current…
- Trial name
- NCT00997139
- Testing
- Neosporin (polymyxin B 5,000units, bacitracin 400 units, neomycin 3.5mg)
- Where
- United States
- Volunteers
- 216 people, healthy volunteers welcome
- Sponsor
- Northwestern University
Staphylococcus Aureus, HIV Infections
Mupirocin Ointment to Eliminate Nasal Carriage of Staphylococcus Aureus in HIV Infection
Staphylococcus aureus is a bacteria that causes serious, often life threatening infections including pneumonia, wound, and bloodstream infections. Persons with AIDS are at high risk for S. aureus infections.
- Trial name
- NCT00801879
- Testing
- Mupirocin calcium ointment, 2%
- Where
- 2 sites in United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Columbia University
Staphylococcus Aureus, Methicillin-resistant Staphylococcus Aureus
Volatile Organic Compounds in Staphylococcus Aureus Patients
The zNose® MRSA test is a non-invasive breath test for markers of Staphylococcus aureus, which may predict the probability of bacterial organisms in the anterior nares, throat and respiratory tract, wounds, and anus and therefore…
- Conditions
- Staphylococcus Aureus, Methicillin-resistant Staphylococcus Aureus, Nosocomial Disease
- Trial name
- MRSAVOC (NCT01379053)
- Where
- United States
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Landon Pediatric Foundation
Staphylococcus Aureus
A Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MEDI4893 in Healthy Adult Subjects
This is a Phase 1, first time in human study enrolling approximately 33 healthy adult subjects (18-65 yrs) from one study site. The purpose of this study is to evaluate the safety, tolerability and PK of MEDI4893 in healthy adult…
- Trial name
- NCT01769417
- Testing
- MEDI4893
- Where
- United States
- Volunteers
- 85 people, healthy volunteers welcome
- Sponsor
- MedImmune LLC
Methicillin-resistant Staphylococcus Aureus, Skin Diseases, Infectious
MRSA Colonization and Control in the Dallas County Jail
The goal of this 3-year project is to control the spread of community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA) in the Dallas County Jail.
- Conditions
- Methicillin-resistant Staphylococcus Aureus, Skin Diseases, Infectious, Soft Tissue Infections
- Trial name
- NCT00785200
- Testing
- Chlorhexidine, Water
- Where
- United States
- Volunteers
- 4,194 people, healthy volunteers welcome
- Sponsor
- University of Chicago